SLC5A2 and chronic kidney disease: Several cardiovascular outcome studies in subjects with T2DM have shown a decreased risk of progression of CKD with SGLT2 inhibitors empagliflozin (in EMPA REG OUTCOME; ClinicalTrials.gov Identifier: NCT01131676) [49], canagliflozin (in CANVAS; ClinicalTrials.gov Identifier: NCT01032629) [51], and dapagliflozin (in DECLARE –TIMI 58; ClinicalTrials.gov Identifier: NCT01730534) [50].